Savella and Niaspan drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Savella (milnacipran hydrochloride) and Niaspan (niacin). Common drug interactions include flushing among females and myoclonic epilepsy among males.

The phase IV clinical study analyzes what interactions people have when they take Savella and Niaspan. It is created by eHealthMe based on reports of 29 people who take the same drugs from the FDA, and is updated regularly.

What is Savella?

Savella has active ingredients of milnacipran hydrochloride. It is often used in fibromyalgia. eHealthMe is studying from 7,529 Savella users. Check the latest studies of Savella.

What is Niaspan?

Niaspan has active ingredients of niacin. It is often used in high blood cholesterol. eHealthMe is studying from 45,453 Niaspan users. Check the latest studies of Niaspan.

On Aug, 09, 2026

29 people who take Savella and Niaspan together, and have interactions are studied.

What are the common drug interactions of Savella and Niaspan, by gender? *:

female:

Flushing (the warm, red condition of human skin)
Injection site mass
Drug hypersensitivity
Sinusitis (inflammation of sinus)
Chest pain
Insomnia (sleeplessness)
Paraesthesia (sensation of tingling, tickling, prickling, pricking, or burning of a person's skin with no apparent long-term physical effect)
Pruritus (severe itching of the skin)
Skin burning sensation
Gait disturbance

male:

Myoclonic epilepsy (type of epilepsy with quick little jerks of the arms, shoulder, or occasionally the legs)
Neuropathy peripheral (surface nerve damage)
Lethargy (tiredness)
Muscle spasms (muscle contraction)
Oedema peripheral (superficial swelling)
Sleep apnoea syndrome (a sleep-related disorder in which the effort to breathe is diminished or absent)
Chronic kidney disease
Renal failure (kidney dysfunction)
Blood pressure increased
Cardiac disorder

What are the common drug interactions of Savella and Niaspan, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

Activities of daily living impaired
Blood pressure increased
Drug hypersensitivity
Fatigue (feeling of tiredness)
Flushing (the warm, red condition of human skin)
Gait disturbance
Generalised erythema (redness of the skin all over the body)
Heart rate increased
Hyperhidrosis (abnormally increased sweating)
Lethargy (tiredness)

50-59:

Injection site mass
Sinusitis (inflammation of sinus)
Anxiety
Asthenia (weakness)
Blood creatinine increased
Blood pressure increased
Cardiac murmur (an heart sound in valve abnormality)
Chest pain
Choking sensation (feeling of obstruction in respiratory system)
Chronic kidney disease

60+:

Myoclonic epilepsy (type of epilepsy with quick little jerks of the arms, shoulder, or occasionally the legs)
Neuropathy peripheral (surface nerve damage)
Chronic kidney disease
Gout (uric acid crystals building up in the body)
Myocardial infarction (destruction of heart tissue resulting from obstruction of the blood supply to the heart muscle)
Renal failure (kidney dysfunction)
Drug hypersensitivity
Dizziness
Injection site mass
Injection site necrosis (death of body tissue at injection site)

What are the existing conditions these people have? *

Pain: 5 people, 17.24%
Narcolepsy (brain's inability to regulate sleep-wake cycles normally): 5 people, 17.24%
Low Density Lipoprotein Increased (cholesterol increased in blood): 5 people, 17.24%
High Density Lipoprotein Decreased: 4 people, 13.79%
Type 2 Diabetes: 3 people, 10.34%
Stress And Anxiety: 2 people, 6.90%
Insomnia (sleeplessness): 2 people, 6.90%
Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 2 people, 6.90%

* Approximation only. Some reports may have incomplete information.

Do you take Savella and Niaspan?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously